دورية أكاديمية
Comparing the efficacy of combined versus single immune cell adaptive therapy targeting colorectal cancer.
العنوان: | Comparing the efficacy of combined versus single immune cell adaptive therapy targeting colorectal cancer. |
---|---|
المؤلفون: | Che DN; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea., Lee N; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea., Lee HJ; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea., Kim YW; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea., Battulga S; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea., Lee HN; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea., Ham WK; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea., Lee H; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea., Lee MY; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea.; Department of Pathology, Seoul Songdo Colorectal Hospital, Seoul, Korea., Kim D; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea., Kang H; Department of Pathology, Seoul Songdo Colorectal Hospital, Seoul, Korea., Yun S; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea., Park J; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea., Won DD; Department of Surgery, Pelvic Floor Center, Seoul Songdo Colorectal Hospital, Seoul, Korea., Lee JK; Immunology Laboratory, Seoul Songdo Colorectal Hospital, Seoul, Korea.; Department of Surgery, Pelvic Floor Center, Seoul Songdo Colorectal Hospital, Seoul, Korea.; Cancer Immune Clinic, Seoul Songdo Colorectal Hospital, Seoul, Korea. |
المصدر: | Annals of coloproctology [Ann Coloproctol] 2024 Apr; Vol. 40 (2), pp. 121-135. Date of Electronic Publication: 2024 Apr 22. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Korean Society of Coloproctology Country of Publication: Korea (South) NLM ID: 101605121 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2287-9714 (Print) Linking ISSN: 22879714 NLM ISO Abbreviation: Ann Coloproctol Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Seoul : Korean Society of Coloproctology, [2013]- |
مستخلص: | Purpose: Colorectal cancer (CRC) is the most frequent cancer with limited therapeutic achievements. Recently, adoptive cellular immunotherapy has been developed as an antitumor therapy. However, its efficacy has not been tested in CRC. This study investigated the ability of an immune cell cocktail of dendritic cells (DCs), T cells, and natural killer (NK) cells to overcome immunological hurdles and improve the therapeutic efficacy of cell therapy for CRC. Methods: CRC lysate-pulsed monocyte-derived DCs (Mo-DCs), CRC antigen-specifically expanded T cells (CTL), and in vitro-expanded NK cells were cultured from patient peripheral blood mononuclear cells (PBMC). The ability of the combined immune cells to kill autologous tumor cells was investigated by co-culturing the combined immune cells with patient-derived tumor cells. Results: The Mo-DCs produced expressed T cell co-stimulating molecules like CD80, CD86, human leukocyte antigen (HLA)-DR and HLA-ABC, at high levels and were capable of activating naive T cells. The expanded T cells were predominantly CD8 T cells with high levels of CD8 effector memory cells and low levels of regulatory T cells. The NK cells expressed high levels of activating receptors and were capable of killing other cancer cell lines (K562 and HT29). The immune cell cocktail demonstrated a higher ability to kill autologous tumor cells than single types. An in vivo preclinical study confirmed the safety of the combined immune cell adaptive therapy showing no therapy-related death or general toxicity symptoms. Conclusion: The results suggested that combined immune cell adaptive therapy could overcome the limited efficacy of cell immunotherapy. |
References: | Signal Transduct Target Ther. 2020 Oct 29;5(1):250. (PMID: 33122640) J Exp Clin Cancer Res. 2022 Feb 19;41(1):68. (PMID: 35183252) Vaccines (Basel). 2021 Nov 19;9(11):. (PMID: 34835294) Prz Gastroenterol. 2019;14(2):89-103. (PMID: 31616522) Signal Transduct Target Ther. 2020 Mar 20;5(1):22. (PMID: 32296018) Cell Mol Immunol. 2020 Aug;17(8):807-821. (PMID: 32612154) Front Oncol. 2022 Apr 06;12:852927. (PMID: 35463300) ACS Appl Bio Mater. 2021 Dec 20;4(12):8291-8300. (PMID: 35005925) Cancer Immunol Immunother. 2014 Oct;63(10):1061-71. (PMID: 24993563) Cancers (Basel). 2020 Dec 21;12(12):. (PMID: 33371456) Br J Cancer. 2019 Jan;120(1):45-53. (PMID: 30413828) Pharmaceuticals (Basel). 2021 Mar 08;14(3):. (PMID: 33800301) Front Immunol. 2020 Jul 28;11:1633. (PMID: 32849557) Front Oncol. 2020 Nov 09;10:569017. (PMID: 33240813) Trends Immunol. 2015 Jan;36(1):49-58. (PMID: 25432489) Front Immunol. 2014 Apr 10;5:159. (PMID: 24782864) Cancers (Basel). 2022 Mar 29;14(7):. (PMID: 35406504) Front Immunol. 2019 Oct 29;10:2534. (PMID: 31736961) BMC Immunol. 2019 Jan 29;20(1):8. (PMID: 30696399) Cancer Cell. 2017 Mar 13;31(3):311-325. (PMID: 28292435) Immunotherapy. 2022 Jun;14(8):639-654. (PMID: 35481358) Clin Cancer Res. 2020 Nov 1;26(21):5689-5700. (PMID: 32788225) Cancers (Basel). 2020 Jul 02;12(7):. (PMID: 32630675) Front Immunol. 2021 Mar 09;12:636568. (PMID: 33767702) |
معلومات مُعتمدة: | Seoul Songdo Colorectal Hospital |
فهرسة مساهمة: | Keywords: Colorectal neoplasms; Combination immunotherapy; Dendritic cells; Natural killer cells; T-lymphocytes |
تواريخ الأحداث: | Date Created: 20240507 Latest Revision: 20240512 |
رمز التحديث: | 20240512 |
مُعرف محوري في PubMed: | PMC11082552 |
DOI: | 10.3393/ac.2023.00402.0057 |
PMID: | 38712438 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2287-9714 |
---|---|
DOI: | 10.3393/ac.2023.00402.0057 |